Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Letue35 

Discuss Cytokinetics Inc.

Cytokinetics Inc.

WKN: A1W1KK / Symbol: CYTK / Name: Cytokinetics / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

54,00 €
3,85 %

Einschätzung Buy
Rendite (%) -42,75 %
Kursziel 82,40
Veränderung
Endet am 12.08.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) -16,89 %
Kursziel 65,15
Veränderung
Endet am 03.09.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) -13,36 %
Kursziel 81,54
Veränderung
Endet am 03.09.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) -9,31 %
Kursziel 63,96
Veränderung
Endet am 05.09.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at JPMorgan Chase & Co. from $65.00 to $71.00. They now have an "overweight" rating on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) -13,20 %
Kursziel 81,51
Veränderung
Endet am 09.09.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) -16,80 %
Kursziel 80,52
Veränderung
Endet am 20.09.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) -2,95 %
Kursziel 80,41
Veränderung
Endet am 30.09.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 5,69 %
Kursziel 109,50
Veränderung
Endet am 09.10.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at HC Wainwright from $90.00 to $120.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) -1,78 %
Kursziel 66,38
Veränderung
Endet am 17.10.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) -1,78 %
Kursziel 110,63
Veränderung
Endet am 17.10.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) -0,96 %
Kursziel 111,07
Veränderung
Endet am 07.11.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 15,31 %
Kursziel 113,52
Veränderung
Endet am 18.11.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 13,54 %
Kursziel 68,18
Veränderung
Endet am 20.11.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 20,73 %
Kursziel 97,75
Veränderung
Endet am 21.11.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at Mizuho from $99.00 to $103.00. They now have an "outperform" rating on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 12,03 %
Kursziel 68,77
Veränderung
Endet am 02.12.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 12,03 %
Kursziel 114,60
Veränderung
Endet am 02.12.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 17,90 %
Kursziel 78,17
Veränderung
Endet am 18.12.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at Royal Bank of Canada from $80.00 to $82.00. They now have an "outperform" rating on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 14,89 %
Kursziel 115,42
Veränderung
Endet am 20.12.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat